No statistically significant difference between mepolizumab and dupilumab in reducing moderate/severe exacerbations in eosinophilic COPD.
Both treatments showed comparable improvements in health-related quality of life as measured by SGRQ-C.
Matching-adjusted indirect comparison (MAIC) methodology allowed adjustment for population differences across clinical trials.
Findings support the interchangeable clinical utility of these monoclonal antibodies targeting type 2 inflammation in COPD patients with high eosinophil counts.
